Site Map


Who should not take PHOTOFRIN? Do not take PHOTOFRIN?

  • If you have a rare disorder with a blood component called porphyria
  • If you have an abnormal connection (fistula) between the esophagus and airways leading to the lungs
  • If you have a tumor extending into a major blood vessel
  • If you have life-threatening breathing failure due to an obstructing airway tumor that requires emergency treatment
  • If you have enlarged veins in the stomach or esophagus or large ulcers in the esophagus

What should I tell my healthcare provider before taking PHOTOFRIN?

Before taking PHOTOFRIN, tell your healthcare provider about all your medical conditions, including if you are:

  • Taking other medicines that are activated by light
  • Taking other medicines during your photodynamic treatment with PHOTOFRIN
  • If you are pregnant or are a nursing mother

What is the most important information I should know about PHOTOFRIN?

  • Sensitivity or allergic reaction to light can be expected; eye sensitivity is possible. This reaction is called phototoxicity, which has a sunburn-like effect and may be severe. All patients receiving PHOTOFRIN will be sensitive to light and must take precautions to avoid exposure of eyes and skin to direct sunlight or bright indoor light for at least 30 days, but it may be required for more than 90 days. The phototoxicity with PHOTOFRIN is unique since it is activated, not only by UV light, but also by light visible to your eyes that is usually safe for humans. Phototoxicity reactions with PHOTOFRIN can occur following the first exposure to direct sunlight or intense indoor light from within a few minutes to up to several hours after exposure; resulting skin damage can persist. After PHOTOFRIN administration, when outside wear protective clothing and dark sunglasses which let less than 4% white light through.
  • An abnormal connection (fistula) can occur if an esophageal tumor is eroding into the main airway leading to the lungs or into one of its branches
  • Holes can develop through the wall of the organs in your digestive system where photodynamic therapy was applied (esophagus, stomach, small intestine, large bowel, rectum, gallbladder)
  • Bleeding can occur if you have enlarged veins in your esophagus
  • Some patients with treated lung cancer lesions are at high risk for coughing up life-threatening amounts of blood
  • If you are being treated for pre-cancerous cells (high-grade dysplasia) in Barrett’s esophagus, biopsy of your esophagus will be performed every 3 months and checked by your doctor until 4 consecutive biopsies are negative for high-grade dysplasia
  • If you require radiotherapy after treatment with PHOTOFRIN, the radiotherapy should not be started until 2-4 weeks after your PHOTOFRIN treatment
  • You may experience chest pain or breathing difficulty. Notify your doctor if you experience chest pain or any other side effects after treatment with PHOTOFRIN. Your doctor may prescribe medication to help reduce the pain.
  • Photodynamic therapy for advanced lung cancer may block the main lung airway, leading to life-threatening difficulty breathing
  • Narrowing of the esophagus occurs frequently after treatment of pre-cancerous cells (high-grade dysplasia) in Barrett’s esophagus
  • If you have liver or kidney problems you may be need to take extra precautions regarding sensitivity to light and for a longer time period
  • Blockage of blood vessels from pieces of a blood clot can happen after treatment with PHOTOFRIN

What are the possible side effects of PHOTOFRIN?

  • For esophageal cancer (treatment of the esophagus): anemia, accumulation of fluid in the lungs, fever, constipation, nausea, chest pain, general pain, stomach pain, difficulty breathing, sensitivity or allergic reaction to light, pneumonia (infection of the lung), vomiting, difficulty sleeping, back pain, inflammation of the throat.
  • For obstructing endobronchial cancer (when cancer blocks the lungs airways): difficulty breathing, sensitivity or allergic reaction to light, coughing with or without small amounts of blood, fever, coughing, pneumonia (infection of the lungs)
  • For superficial endobronchial tumors (when cancer slightly invades surrounding tissues): fluid leaking out of blood vessels nearby tissue, sensitivity or allergic reaction to light, blockage lung airways, swelling of tissue due to large fluid volume, narrowing of the main airway leading to lungs
  • High-grade dysplasia (pre-cancerous cells) in Barrett’s Esophagus (treatment of the esophagus): sensitivity or allergic reaction to light, narrowing of the esophagus, vomiting, chest pain, nausea, fever, constipation, difficulty or pain when swallowing, abdominal pain, accumulation of fluid in the lungs, dehydration.

These are not all the possible side effects of PHOTOFRIN. For more information call your healthcare provider. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088 or call Concordia Laboratories Inc. at 1-866-248-2039.


PHOTOFRIN is used for:

Esophageal Cancer

  • Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy

Endobronchial Cancer

  • Treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated
  • Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC

High-Grade Dysplasia in Barrett's Esophagus

  • Ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy
Please see Full Prescribing Information.


PHOTOFRIN®, Pinnacle Biologics™ and the logo of Pinnacle Biologics™ are trademarks of Pinnacle Biologics, Inc. See more.

The PHOTOFRIN® trademark is owned by Concordia Laboratories Inc.

PHOTOFRIN® is manufactured for Concordia Laboratories Inc. and distributed in the United States by Pinnacle Biologics Inc. See more.